| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Monday after the company announced that it has entered into a collaboration agreement with Univercells Group to evaluate the use of the company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
The Details:
Under the terms of the agreement, Univercells will test a proprietary mRNA vaccine delivered with Altamira’s SemaPhore nanoparticle platform. If the experiments are successful, the companies intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.
“We are thrilled to initiate this collaboration with Univercells to explore SemaPhore as a delivery vehicle for mRNA vaccines”, commented Covadonga Pañeda, PhD, Altamira’s COO.
“SemaPhore has shown to be an efficient delivery vehicle for therapeutic RNA in many different disease models. With this collaboration we will explore for the first time its potential utility in delivering mRNA vaccines."
Altamira shares are climbing on heavy trading volume following the announcement. According to data from Benzinga Pro, more than 51.2 million shares have been traded in the session, compared to the stock’s 100-day average of less than 188,000 shares.
Related News: What’s Going On With Marijuana Stocks Tilray And Canopy Growth As Germany Legalizes Pot?
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Altamira Therapeutics‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Altamira Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 19.67%, you'll need to buy a share of Dividend Gwth Split by the Mar. 27, 2024. Once done, you can expect to receive a nominal payout of $0.1 on Apr. 12, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on Altamira Therapeutics will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
CYTO Price Action: According to Benzinga Pro, Altamira Therapeutics shares are up 48.5% at $2.57 at the time of publication Monday.
Image: Steve Buissine from Pixabay
Posted In: CYTO
